Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

370
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
370
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

3.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.0K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

191
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
191

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced bioavailability of anemoside B4 by dry powder inhalation mitigates high-altitude acute lung injury.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026
Same author

Pulmonary delivery of low-dose dexamethasone significantly reduces toxicity in acute lung injury therapy.

International journal of pharmaceutics·2026
Same author

Design and evaluation of cyanocobalamin nasal powders for nasal delivery using biomimetic nasal cavity models.

Journal of pharmaceutical sciences·2025
Same author

Three-Compartment Pharmacokinetics of Inhaled and Injected Sinapine Thiocyanate Manifest Prolonged Retention and Its Therapeutics in Acute Lung Injury.

Pharmaceutics·2025
Same author

A smart grid data sharing scheme supporting policy update and traceability.

Scientific reports·2025
Same author

Incorporation of Mometasone Furoate into a Cyclodextrin Metal-Organic Framework to Optimize Nasal Administration.

Pharmaceutics·2025

Related Experiment Video

Updated: Sep 2, 2025

Direct Tracheal Instillation of Solutes into Mouse Lung
04:50

Direct Tracheal Instillation of Solutes into Mouse Lung

Published on: August 29, 2010

29.4K

Antioxidant Biodegradable Covalent Cyclodextrin Frameworks as Particulate Carriers for Inhalation Therapy against

Siyu He1,2, Li Wu1, Hongyu Sun1

  • 1Center for Drug Delivery Systems, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

ACS Applied Materials & Interfaces
|August 10, 2022
PubMed
Summary

This study introduces novel, ROS-sensitive inhalable frameworks (OC-COF) loaded with Ligustrazine (LIG) for treating acute lung injury (ALI). LIG@OC-COF effectively reduced inflammation and lung damage in rats, offering a promising drug delivery strategy.

Keywords:
acute lung injurycovalent cyclodextrin frameworksligustrazinepulmonary drug deliveryreactive oxygen species-sensitive

More Related Videos

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting
08:53

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting

Published on: March 28, 2025

504
A Model of Self-limited Acute Lung Injury by Unilateral Intra-bronchial Acid Instillation
07:40

A Model of Self-limited Acute Lung Injury by Unilateral Intra-bronchial Acid Instillation

Published on: August 30, 2019

9.1K

Related Experiment Videos

Last Updated: Sep 2, 2025

Direct Tracheal Instillation of Solutes into Mouse Lung
04:50

Direct Tracheal Instillation of Solutes into Mouse Lung

Published on: August 29, 2010

29.4K
Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting
08:53

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting

Published on: March 28, 2025

504
A Model of Self-limited Acute Lung Injury by Unilateral Intra-bronchial Acid Instillation
07:40

A Model of Self-limited Acute Lung Injury by Unilateral Intra-bronchial Acid Instillation

Published on: August 30, 2019

9.1K

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Pharmacology

Background:

  • Current drug therapies for acute lung injury (ALI) lack specific lung targeting, limiting efficacy.
  • Inhalable drug delivery to deep lung regions is critical for ALI treatment.
  • Conventional inhalable carriers are often pharmacologically inactive, necessitating novel approaches.

Purpose of the Study:

  • To synthesize a novel, biodegradable, and reactive oxygen species (ROS)-sensitive carrier for pulmonary drug delivery.
  • To develop an inhalable dry powder formulation (LIG@OC-COF) for synergistic treatment of ALI.
  • To evaluate the therapeutic efficacy of LIG@OC-COF in an ALI rat model.

Main Methods:

  • Synthesis of ROS-sensitive cross-linked covalent cyclodextrin frameworks (OC-COF) with peroxalate ester linkages.
  • Loading of Ligustrazine (LIG), an antioxidant and anti-inflammatory agent, into OC-COF.
  • In vitro and in vivo evaluation of LIG@OC-COF aerodynamic properties, antioxidant/anti-inflammatory capacities, and therapeutic effects in ALI rats, including Western blot analysis of the Nrf2/NF-κB pathway.

Main Results:

  • OC-COF demonstrated ROS-scavenging capabilities and favorable aerodynamic properties when formulated as LIG@OC-COF.
  • LIG@OC-COF exhibited significant synergistic antioxidant and anti-inflammatory effects.
  • Inhalation of LIG@OC-COF in ALI rats significantly reduced inflammation, oxidative stress, and lung damage, regulating the Nrf2/NF-κB signaling pathway.

Conclusions:

  • The developed ROS-responsive OC-COF serves as an effective inhalable carrier for pulmonary drug delivery.
  • LIG@OC-COF offers a synergistic therapeutic approach for ALI treatment with improved efficacy and reduced drug dosage.
  • This novel material holds potential for treating ALI and other inflammatory lung conditions.